Literature DB >> 17726105

ALL1 fusion proteins induce deregulation of EphA7 and ERK phosphorylation in human acute leukemias.

Hiroshi Nakanishi1, Tatsuya Nakamura, Eli Canaani, Carlo M Croce.   

Abstract

Erythropoietin-producing hepatoma-amplified sequence (Eph) receptor tyrosine kinases and their cell-surface-bound ligands, the ephrins, function as a unique signaling system triggered by cell-to-cell interaction and have been shown to mediate neurodevelopmental processes. In addition, recent studies showed deregulation of some of Eph/ephrin genes in human malignancies, suggesting the involvement of this signaling pathway in tumorigenesis. The ALL1 (also termed MLL) gene on human chromosome 11q23 was isolated by virtue of its involvement in recurrent chromosome translocations associated with acute leukemias with poor prognosis. The translocations fuse ALL1 to any of >50 partner genes and result in production of chimeric proteins composed of the ALL1 N terminus and the C terminus of the partner protein. The most common translocations in ALL1-associated leukemias are t(4;11) and t(9;11), which generate ALL1/AF4 and ALL1/AF9 fusion protein, respectively. In the present study, we sought to determine whether ALL1 fusion proteins are involved in regulation of Eph/ephrin genes. Screening of K562 cells producing recombinant ALL1/AF4 or ALL1/AF9 fusion protein revealed transcriptional up-regulation of the EphA7. Consistent with this finding, siRNA-mediated suppression of ALL1/AF4 in SEMK2 cells carrying the t(4;11) chromosome translocation resulted in down-regulation of EphA7. ChIP analysis demonstrated the occupancy of tagged ALL1 fusion proteins on the EphA7 promoter, pointing to EphA7 as a direct target of the formers. Further studies demonstrate that EphA7 up-regulation is accompanied by ERK phosphorylation. Finally, we show apoptotic cell death, specific for leukemic cells carrying the t(4;11) chromosome translocation, after treatment of the cells with an ERK phosphorylation blocker.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17726105      PMCID: PMC1964835          DOI: 10.1073/pnas.0703211104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  24 in total

1.  Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization.

Authors:  Bernd B Zeisig; Tom Milne; María-Paz García-Cuéllar; Silke Schreiner; Mary-Ellen Martin; Uta Fuchs; Arndt Borkhardt; Sumit K Chanda; John Walker; Richard Soden; Jay L Hess; Robert K Slany
Journal:  Mol Cell Biol       Date:  2004-01       Impact factor: 4.272

2.  The t(4;11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax, to the AF-4 gene.

Authors:  Y Gu; T Nakamura; H Alder; R Prasad; O Canaani; G Cimino; C M Croce; E Canaani
Journal:  Cell       Date:  1992-11-13       Impact factor: 41.582

3.  Overexpression of the EphA2 tyrosine kinase in prostate cancer.

Authors:  J Walker-Daniels; K Coffman; M Azimi; J S Rhim; D G Bostwick; P Snyder; B J Kerns; D J Waters; M S Kinch
Journal:  Prostate       Date:  1999-12-01       Impact factor: 4.104

4.  MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia.

Authors:  Scott A Armstrong; Jane E Staunton; Lewis B Silverman; Rob Pieters; Monique L den Boer; Mark D Minden; Stephen E Sallan; Eric S Lander; Todd R Golub; Stanley J Korsmeyer
Journal:  Nat Genet       Date:  2001-12-03       Impact factor: 38.330

5.  EphA2 overexpression causes tumorigenesis of mammary epithelial cells.

Authors:  D P Zelinski; N D Zantek; J C Stewart; A R Irizarry; M S Kinch
Journal:  Cancer Res       Date:  2001-03-01       Impact factor: 12.701

6.  Expression profiles of acute lymphoblastic and myeloblastic leukemias with ALL-1 rearrangements.

Authors:  T Rozovskaia; O Ravid-Amir; S Tillib; G Getz; E Feinstein; H Agrawal; A Nagler; E F Rappaport; I Issaeva; Y Matsuo; U R Kees; T Lapidot; F Lo Coco; R Foa; A Mazo; T Nakamura; C M Croce; G Cimino; E Domany; E Canaani
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-02       Impact factor: 11.205

7.  EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma.

Authors:  Tatsuya Miyazaki; Hiroyuki Kato; Minoru Fukuchi; Masanobu Nakajima; Hiroyuki Kuwano
Journal:  Int J Cancer       Date:  2003-02-20       Impact factor: 7.396

8.  Expression of Ephb2 and Ephb4 in breast carcinoma.

Authors:  Qinghua Wu; Zhenhe Suo; Bjørn Risberg; Mats G Karlsson; Kenneth Villman; Jahn M Nesland
Journal:  Pathol Oncol Res       Date:  2004-03-18       Impact factor: 3.201

9.  Induction of apoptosis in BCR/ABL+ cells by histone deacetylase inhibitors involves reciprocal effects on the RAF/MEK/ERK and JNK pathways.

Authors:  Chunrong Yu; Mark Subler; Mohamed Rahmani; Erin Reese; Geoffrey Krystal; Daniel Conrad; Paul Dent; Steven Grant
Journal:  Cancer Biol Ther       Date:  2003 Sep-Oct       Impact factor: 4.742

10.  MEKK1 phosphorylates MEK1 and MEK2 but does not cause activation of mitogen-activated protein kinase.

Authors:  S Xu; D Robbins; J Frost; A Dang; C Lange-Carter; M H Cobb
Journal:  Proc Natl Acad Sci U S A       Date:  1995-07-18       Impact factor: 11.205

View more
  25 in total

1.  Grist for the MLL: how do MLL oncogenic fusion proteins generate leukemia stem cells?

Authors:  Tim C P Somervaille; Michael L Cleary
Journal:  Int J Hematol       Date:  2010-05-08       Impact factor: 2.490

2.  EphA7 regulates spiral ganglion innervation of cochlear hair cells.

Authors:  Young J Kim; Leena A Ibrahim; Sheng-Zhi Wang; Wei Yuan; Oleg V Evgrafov; James A Knowles; Kai Wang; Huizhong W Tao; Li I Zhang
Journal:  Dev Neurobiol       Date:  2015-07-27       Impact factor: 3.964

Review 3.  Two decades of leukemia oncoprotein epistasis: the MLL1 paradigm for epigenetic deregulation in leukemia.

Authors:  Bin E Li; Patricia Ernst
Journal:  Exp Hematol       Date:  2014-09-28       Impact factor: 3.084

4.  Mechanisms of mixed-lineage leukemia.

Authors:  Andrew G Muntean
Journal:  Int J Hematol Oncol       Date:  2013-06-01

5.  Loss of miR-125b-1 contributes to head and neck cancer development by dysregulating TACSTD2 and MAPK pathway.

Authors:  H Nakanishi; C Taccioli; J Palatini; C Fernandez-Cymering; R Cui; T Kim; S Volinia; C M Croce
Journal:  Oncogene       Date:  2013-02-18       Impact factor: 9.867

6.  Molecular targeting of MLL-rearranged leukemia cell lines with the synthetic peptide PFWT synergistically enhances the cytotoxic effect of established chemotherapeutic agents.

Authors:  Cecily A Bennett; Amanda C Winters; Nisha N Barretto; Charles S Hemenway
Journal:  Leuk Res       Date:  2009-02-20       Impact factor: 3.156

7.  EPHA7 and EPHA10 Physically Interact and Differentially Co-localize in Normal Breast and Breast Carcinoma Cell Lines, and the Co-localization Pattern Is Altered in EPHB6-expressing MDA-MB-231 Cells.

Authors:  Candace Johnson; Briana Segovia; Raj P Kandpal
Journal:  Cancer Genomics Proteomics       Date:  2016 09-10       Impact factor: 4.069

Review 8.  Therapeutic targeting of MLL.

Authors:  Michaela Liedtke; Michael L Cleary
Journal:  Blood       Date:  2009-03-16       Impact factor: 22.113

Review 9.  Chromatin modifications as therapeutic targets in MLL-rearranged leukemia.

Authors:  Aniruddha J Deshpande; James Bradner; Scott A Armstrong
Journal:  Trends Immunol       Date:  2012-08-03       Impact factor: 16.687

Review 10.  Putative miRNAs for the diagnosis of dyslexia, dyspraxia, and specific language impairment.

Authors:  Alexander Rudov; Marco Bruno Luigi Rocchi; Augusto Accorsi; Giorgio Spada; Antonio Domenico Procopio; Fabiola Olivieri; Maria Rita Rippo; Maria Cristina Albertini
Journal:  Epigenetics       Date:  2013-08-15       Impact factor: 4.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.